GT719 Injection for the Treatment of Recurrent/Refractory CD19 Positive Adult B-cell Malignancies

Inclusion criteria

• Voluntarily enrolled in the study, signed an informed consent form, and willing and able to comply with the study protocol.

-

• Eastern Collaborative Oncology Group (ECOG) physical fitness status score of 0 or 1.

-

• CD19 positivity confirmed by flow cytometry and/or histopathology.

Exclusion criteria

• Primary immunodeficiency.

-

• History of symptomatic deep vein thrombosis or pulmonary embolism within 6 months prior to enrollment, requiring systemic anticoagulant therapy.

-

• Any medical condition that may interfere with the evaluation of the safety or effectiveness of research and treatment;